{"product_id":"birlafertility-pestle-analysis","title":"Birla Fertility \u0026 IVF PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our PESTLE Analysis of Birla Fertility \u0026amp; IVF—uncover how political, economic, social, technological, legal, and environmental forces will shape growth and risk; buy the full report for a ready-to-use, deeply researched breakdown you can apply to investment, strategy, or competitive analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Infrastructure Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Indian government scaled up healthcare spending to 2.1% of GDP by 2024–25 and expanded Ayushman Bharat to cover over 650 million people, strengthening public health infrastructure that complements private fertility services like Birla Fertility \u0026amp; IVF.\u003c\/p\u003e\n\u003cp\u003ePolicymaker recognition of infertility as a public health concern has driven state-level infertility programs and subsidies, creating incentives for private providers to expand; Birla can leverage this to enter Tier 2–3 markets where outpatient volumes grew ~12% YoY in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Tourism Promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment push to make India a medical value travel hub—visa facilitation and incentives—boosts Birla Fertility \u0026amp; IVF by enlarging its international patient pool; medical tourism arrivals grew 24% in 2024 to ~675,000, and fertility treatments represent a rising segment. Alignment with national tourism drives and state incentives opens markets in Southeast Asia and Africa where outbound fertility demand rose an estimated 18% in 2023–24, increasing revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Health Mission Alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegration with National Health Mission goals on maternal and reproductive health gives Birla Fertility \u0026amp; IVF a policy framework for clinical standards and reporting; NHM targets reduced maternal mortality (MMR 97\/100,000 in 2018–20) and improved reproductive services funding that affects private partnerships.\u003c\/p\u003e\n\u003cp\u003eAlthough IVF is predominantly private, increasing political focus on reproductive outcomes—e.g., state audits and mandatory reporting trends after 2020—pressures clinics to standardize success-rate disclosures and quality metrics.\u003c\/p\u003e\n\u003cp\u003eBirla Fertility \u0026amp; IVF must align with evolving public-health priorities and compliance requirements to protect market share in India’s organized fertility market, valued around USD 1.5–2.0 billion in 2024 and growing at ~10–12% CAGR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-Border Healthcare Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of late 2025, strained geopolitics reduced inbound medical tourists to India by ~8% YoY, impacting Birla Fertility’s international patient mix; import restrictions raised costs for specialized incubators and vitrification kits by 12–18%.\u003c\/p\u003e\n\u003cp\u003ePolitical stability and bilateral healthcare MOUs—15 signed by India through 2024—remain pivotal for market entry, influencing projected international revenue growth assumptions of 10–15% CAGR.\u003c\/p\u003e\n\u003cp\u003eShifts in trade tariffs on medical consumables could increase ART procedure OPEX by up to 7%, affecting pricing and margin strategies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInbound medical tourists down ~8% YoY (late 2025)\u003c\/li\u003e\n\u003cli\u003eImport cost inflation for equipment 12–18%\u003c\/li\u003e\n\u003cli\u003e15 bilateral healthcare MOUs through 2024\u003c\/li\u003e\n\u003cli\u003ePotential OPEX rise up to 7% from tariff changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-Private Partnership Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Indian government is expanding public-private partnerships in healthcare, with PPP spending rising to an estimated 2.1% of GDP in 2024 and targeted grants of INR 12,000 crore for specialized care initiatives in FY2024–25, creating opportunities for private providers. Birla Fertility \u0026amp; IVF can partner on research, training, and community reproductive health programs, leveraging clinical expertise to access government grants and potential tax incentives. Such collaborations can boost brand credibility and align operations with national health missions like the National Health Policy 2025, which emphasizes private sector participation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePPP healthcare funding ~INR 12,000 crore FY2024–25\u003c\/li\u003e\n\u003cli\u003eGovernment PPP focus: National Health Policy 2025\u003c\/li\u003e\n\u003cli\u003eOpportunities: grants, tax incentives, enhanced reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy, tourism surge \u0026amp; cost pressures reshape Birla Fertility’s expansion and pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical support for healthcare (2.1% of GDP 2024–25), 15 bilateral health MOUs through 2024, PPP grants ~INR 12,000 crore, 24% rise in medical tourists 2024 (then -8% YoY late 2025), import cost inflation 12–18%, tariff-driven OPEX risk ~7%—all shape Birla Fertility \u0026amp; IVF’s expansion, compliance and pricing strategies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eIndicator\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth spend\u003c\/td\u003e\n\u003ctd\u003e2.1% GDP (2024–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical tourists\u003c\/td\u003e\n\u003ctd\u003e+24% (2024); -8% (late 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePPP grants\u003c\/td\u003e\n\u003ctd\u003eINR 12,000cr (FY24–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImport inflation\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOPEX risk\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Birla Fertility \u0026amp; IVF across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to support executives, consultants, and investors in spotting risks and opportunities for strategy, funding, and scenario planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Birla Fertility \u0026amp; IVF that eases meeting prep and presentations, supports quick risk discussions and market positioning, and is easily editable and shareable for teams and consultants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Disposable Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe expanding Indian middle class and rise in dual-income households have increased affordability for premium fertility care; household consumption rose 7.5% YoY in FY2024–25, supporting discretionary health spend. As of 2025, elective procedures like egg freezing account for ~18–22% of urban IVF demand, enabling Birla Fertility to reinforce premium pricing and comprehensive high-end reproductive packages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion of Insurance Coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, inclusion of infertility treatments in corporate and private health plans rose to an estimated 30-40% of large employers, cutting average out-of-pocket IVF costs by roughly 40%, which lowers barriers for couples. For Birla Fertility \u0026amp; IVF, this boosts insured patient volumes—management estimates a 15-25% increase—and creates more predictable revenue from claims reimbursements, improving ARPU and margin visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of Advanced Medical Imports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBirla Fertility \u0026amp; IVF faces exposure to currency swings and import duties as ~70% of advanced IVF incubators, ICSI rigs and culture media are imported, making capex for new clinics sensitive to INR volatility; a 10% rupee depreciation could raise equipment costs by roughly 8–12% based on 2024 import price indices. Managing this via strategic sourcing, bulk procurement and local OEM partnerships helps contain unit capex and preserve competitive pricing in a market where average IVF cycle prices range ₹1.2–2.5 lakh. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Consolidation and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe fertility sector in 2025 shows strong consolidation as organized chains like Birla Fertility \u0026amp; IVF acquire independent clinics; India saw ~18% M\u0026amp;A deal value growth in healthcare 2024–25 with fertility a key subsegment.\u003c\/p\u003e\n\u003cp\u003eCK Birla Group capital access enables rapid scaling—Birla has expanded to 40+ centers by 2025—funding supports capex and talent deployment.\u003c\/p\u003e\n\u003cp\u003eStable funding sustains R\u0026amp;D investment, boosting clinical outcomes; centers report incremental success-rate improvements of 2–4 percentage points after protocol upgrades.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConsolidation: rising M\u0026amp;A, 18% deal growth (2024–25)\u003c\/li\u003e\n\u003cli\u003eScale: 40+ Birla centers by 2025\u003c\/li\u003e\n\u003cli\u003eFunding edge: CK Birla capital for capex and hiring\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D impact: +2–4 pp in success rates post-investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Inflation Impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical inflation—driven by a ~7–9% annual rise in healthcare wages and a 6%+ increase in lab equipment\/consumables (2024 India estimates)—raises operating costs for Birla Fertility, pressuring margins as it must keep IVF cycles affordable for Indian consumers.\u003c\/p\u003e\n\u003cp\u003eTo offset, the company targets operational efficiencies: automating admin workflows, consolidating labs, and deploying tech to reduce per-cycle costs while maintaining quality.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWage inflation ~7–9% (2024 India)\u003c\/li\u003e\n\u003cli\u003eLab consumables up ~6%+\u003c\/li\u003e\n\u003cli\u003eFocus: automation, lab consolidation, efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising middle class, employer coverage fuel 15–25% IVF volume growth amid cost pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising middle class and dual incomes lift elective IVF demand (~18–22% urban); household consumption +7.5% FY2024–25. Employer coverage rose to 30–40% by 2025, cutting OOP ~40% and boosting insured volumes 15–25%. 70% of advanced equipment imported; 10% INR depreciation → +8–12% equipment cost. Medical inflation: wages +7–9%, consumables +6%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrban elective IVF share\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployer coverage\u003c\/td\u003e\n\u003ctd\u003e30–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHousehold consumption growth\u003c\/td\u003e\n\u003ctd\u003e+7.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImported equipment share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical wage inflation\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eBirla Fertility \u0026amp; IVF PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Birla Fertility \u0026amp; IVF PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751696150905,"sku":"birlafertility-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/birlafertility-pestle-analysis.png?v=1772234124","url":"https:\/\/matrixbcg.com\/products\/birlafertility-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}